The agonist of CB2R JWH-015 was assessed in an in vivo tumourigenesis model and had the ability to inhibit the EMT process of LC cells by down-regulating EGFR signalling which is usually markedly increased in LC [118]. This evidence concerns the gene EGFR and laryngotracheoesophageal cleft.